Opinion|Videos|November 18, 2026

Evaluating Non-BRCA HRR Alterations for PARP Inhibitor Therapy

The panelists frame biomarker evaluation as a sequence of analytic validity, clinical validity, and clinical utility.

The panelists frame biomarker evaluation as a sequence of analytic validity, clinical validity, and clinical utility. TP53 loss can be measured reliably and predicts worse outcomes, yet lacks utility because no treatment matches it, whereas BRCA2 alterations meet every standard for PARP inhibitor therapy. The discussion then addresses non-BRCA homologous recombination repair alterations such as ATM, CHEK2, PALB2, and CDK12. The panelists review TALAPRO-3, which evaluated talazoparib plus enzalutamide vs enzalutamide alone in HRR-altered metastatic hormone-sensitive prostate cancer and showed a substantial radiographic progression-free survival benefit that was consistent across BRCA and non-BRCA subgroups, including ATM and CDK12, while noting that regulatory approval is still pending. They also reference an FDA pooled analysis comparing PARP inhibitor monotherapy with combinations by gene. ATM remains the most challenging alteration because of clonal hematopoiesis, and the panelists advise confirming ATM alterations in tissue unless the circulating tumor DNA assay screens for clonal hematopoiesis.


Related to this article